Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Five Prime Therapeutics patents

List of Five Prime Therapeutics patents

List of Merge Healthcare patents

List of Charm Sciences, Inc. patents

List of BSH Hausgeräte patents

List of funding rounds for eSentire

List of companies in MP Healthcare Venture Management's investment portfolio

Patents where

Current Assignee

Name

is

Five Prime Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 7678890 Compositions and methods of treating disease with FGFR fusion proteins	Patent 7678890 was granted and assigned to Five Prime Therapeutics on March, 2010 by the United States Patent and Trademark Office.		Five Prime Therapeutics		United States Patent and Trademark Office	7678890	March 16, 2010
	‌ US Patent 7776564 Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use	Patent 7776564 was granted and assigned to Five Prime Therapeutics on August, 2010 by the United States Patent and Trademark Office.		Five Prime Therapeutics		United States Patent and Trademark Office	7776564	August 17, 2010
	‌ US Patent 7982014 FGFR3-IIIc fusion proteins	Patent 7982014 was granted and assigned to Five Prime Therapeutics on July, 2011 by the United States Patent and Trademark Office.		Five Prime Therapeutics		United States Patent and Trademark Office	7982014	July 19, 2011
	‌ US Patent 11559583 Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer	Patent 11559583 was granted and assigned to Five Prime Therapeutics on January, 2023 by the United States Patent and Trademark Office.	Five Prime Therapeutics	Five Prime Therapeutics		United States Patent and Trademark Office	11559583	January 24, 2023
	‌ US Patent 8173134 ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them	Patent 8173134 was granted and assigned to Five Prime Therapeutics on May, 2012 by the United States Patent and Trademark Office.		Five Prime Therapeutics		United States Patent and Trademark Office	8173134	May 8, 2012
	‌ US Patent 7795404 Human soluble notch receptor ligands	Patent 7795404 was granted and assigned to Five Prime Therapeutics on September, 2010 by the United States Patent and Trademark Office.		Five Prime Therapeutics		United States Patent and Trademark Office	7795404	September 14, 2010
	‌ US Patent 8501191 FGFR2-IIIb fusion proteins and methods of making them			Five Prime Therapeutics		United States Patent and Trademark Office	8501191	August 6, 2013
	‌ US Patent 11939383 B7-H4 antibodies and methods and use thereof	Patent 11939383 was granted and assigned to Five Prime Therapeutics on March, 2024 by the United States Patent and Trademark Office.	Five Prime Therapeutics	Five Prime Therapeutics		United States Patent and Trademark Office	11939383	March 26, 2024
	‌ US Patent 11789010 Methods of treatment with CD80 extracellular domain polypeptides	Patent 11789010 was granted and assigned to Five Prime Therapeutics on October, 2023 by the United States Patent and Trademark Office.	Five Prime Therapeutics	Five Prime Therapeutics		United States Patent and Trademark Office	11789010	October 17, 2023

9 results

0 selected

9 results

0 selected